COVID-19 studies for: C19 studies:  HC QHC Q Vitamin DVitamin D IvermectinIVM LY-CoVLY REGN-COV2REGN RemdesivirRMD
HC Q study #132
Source   PDF   Share   Tweet
See all 143 studies
Late treatment study
Lammers et al., Int. J. Infectious Diseases, doi:10.1016/j.ijid.2020.09.1460 (Peer Reviewed)
Observational study 1,064 hospitalized patients in the Netherlands, 53% reduced risk of transfer to the ICU for mechanical ventilation with HC Q treatment starting on the first day of admission.
Weighted propensity score adjusted hazard ratio for transfer to the ICU with HC Q treatment, HR = 0.47, p = 0.008. For C Q, HR = 0.8, p = 0.207. Mortality results in this study are only for mortality before transfer to the ICU. The combined ICU/death HR was 0.68, p = 0.024 for HC Q, and 0.85, p = 0.224 for C Q.
Observational, multicenter, cohort study of hospitalized COVID-19 patients. 189 HC Q patients, 377 C Q, 498 control.
combined death/ICU, ↓32.0%, p=0.02
Source   PDF   Share   Tweet
See all 143 studies
Please send us corrections, updates, or comments.